Goldman Sachs
IMNP

Goldman Sachs’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Goldman Sachs’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-28,405
Closed -$10K – 6250
2018
Q1 		$10K Buy
+28,405
New +$13.5K ﹤0.01% 5758
2017
Q3 		– Sell
-10,798
Closed -$33K – 7023
2017
Q2 		$33K Buy
10,798
+9,010
+504% +$24.2K ﹤0.01% 6460
2017
Q1 		$5K Sell
1,788
-23
-1% -$83 ﹤0.01% 6662
2016
Q4 		$7K Sell
1,811
-6,032
-77% -$24.8K ﹤0.01% 6799
2016
Q3 		$44K Buy
+7,843
New +$57.9K ﹤0.01% 6524
2016
Q1 		– Sell
-1,692
Closed -$25K – 7471
2015
Q4 		$25K Buy
1,692
+200
+13% +$4.2K ﹤0.01% 6797
2015
Q3 		$35K Buy
1,492
+71
+5% +$2.23K ﹤0.01% 6908
2015
Q2 		$55K Sell
1,421
-260
-15% -$10.3K ﹤0.01% 6842
2015
Q1 		$60K Buy
1,681
+44
+3% +$1.65K ﹤0.01% 6635
2014
Q4 		$62K Buy
1,637
+80
+5% +$4.3K ﹤0.01% 6746
2014
Q3 		$105K Buy
+1,557
New +$111K ﹤0.01% 6561

Other funds holding IMNP

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's IMNP Position: Q2 2018 in Review

Goldman Sachs sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2018, closing a stake of 28,405 shares — an estimated $10K sold.

Goldman Sachs first reported a position in IMNP in Q3 2014 and held it in 11 quarters. The position peaked at $105K in Q3 2014. 13 funds tracked by Wall St. Rank hold IMNP as of Q2 2018.

  • Goldman Sachs reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Goldman Sachs sold 28,405 Immune Pharmaceuticals Inc. shares in Q2 2018, an estimated $10K.
  • Goldman Sachs first reported a position in Immune Pharmaceuticals Inc. in Q3 2014 and held it in 11 quarters.
  • Goldman Sachs's Immune Pharmaceuticals Inc. position peaked at $105K in Q3 2014.
  • 13 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2018.

Based on Goldman Sachs's 13F filing for Q2 2018, filed 14 Aug 2018.